Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 23, 2017

Study Completion Date

December 6, 2017

Conditions
Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolus
Interventions
DRUG

Twice daily enoxaparin prophylaxis

Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.

DRUG

Real time dose adjustment

Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.

Trial Locations (1)

84132

University of Utah Hospitals, Salt Lake City

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

University of Utah

OTHER

NCT02687204 - Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients | Biotech Hunter | Biotech Hunter